NO20084307L - Heterocykliske GPCR agonister - Google Patents

Heterocykliske GPCR agonister

Info

Publication number
NO20084307L
NO20084307L NO20084307A NO20084307A NO20084307L NO 20084307 L NO20084307 L NO 20084307L NO 20084307 A NO20084307 A NO 20084307A NO 20084307 A NO20084307 A NO 20084307A NO 20084307 L NO20084307 L NO 20084307L
Authority
NO
Norway
Prior art keywords
gpcr agonists
heterocyclic
agonists
heterocyclic gpcr
treatment
Prior art date
Application number
NO20084307A
Other languages
English (en)
Norwegian (no)
Inventor
Matthew Colin Thor Fyfe
Lisa Sarah Bertram
Martin James Procter
Geoffrey Martyn Williams
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606913A external-priority patent/GB0606913D0/en
Priority claimed from GB0700112A external-priority patent/GB0700112D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of NO20084307L publication Critical patent/NO20084307L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20084307A 2006-04-06 2008-10-15 Heterocykliske GPCR agonister NO20084307L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0606913A GB0606913D0 (en) 2006-04-06 2006-04-06 Compounds
GB0700112A GB0700112D0 (en) 2007-01-04 2007-01-04 Compounds
PCT/GB2007/050183 WO2007116229A1 (fr) 2006-04-06 2007-04-05 Agonistes gpcr hétérocycliques

Publications (1)

Publication Number Publication Date
NO20084307L true NO20084307L (no) 2008-10-28

Family

ID=38227799

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084307A NO20084307L (no) 2006-04-06 2008-10-15 Heterocykliske GPCR agonister

Country Status (12)

Country Link
US (1) US20090221639A1 (fr)
EP (1) EP2013201B1 (fr)
JP (1) JP2009532453A (fr)
KR (1) KR20080109075A (fr)
AU (1) AU2007235673A1 (fr)
BR (1) BRPI0710839A2 (fr)
CA (1) CA2646676A1 (fr)
MX (1) MX2008012814A (fr)
NO (1) NO20084307L (fr)
NZ (1) NZ571869A (fr)
WO (1) WO2007116229A1 (fr)
ZA (1) ZA200809289B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700125D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EP2114936A1 (fr) * 2007-01-04 2009-11-11 Prosidion Limited Agonistes de gpcr pipéridiniques
AR064735A1 (es) * 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
PE20081849A1 (es) * 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
GB0700122D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
ES2373181T3 (es) * 2007-01-04 2012-02-01 Prosidion Ltd Agonistas de gpcr de piperidina.
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2200609A1 (fr) * 2007-09-10 2010-06-30 Prosidion Limited Composés pour le traitement de troubles métaboliques
AU2008302570B2 (en) 2007-09-20 2012-05-31 Irm Llc Compounds and compositions as modulators of GPR119 activity
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
WO2009117421A2 (fr) * 2008-03-17 2009-09-24 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
EP2108960A1 (fr) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
CA2724426A1 (fr) * 2008-05-19 2009-11-26 Schering Corporation Derives heterocycliques bicycliques et leur utilisation en tant que modulateurs de gpr119
WO2010084512A1 (fr) 2008-12-24 2010-07-29 Cadila Healthcare Limited Nouveaux dérivés d'oxime
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
ES2459950T3 (es) 2009-08-05 2014-05-13 Daiichi Sankyo Company, Limited 4-(1,2,4-dioxazol-3-il)benzamidas para el tratamiento de la diabetes y la obesidad
WO2011016470A1 (fr) 2009-08-05 2011-02-10 第一三共株式会社 Dérivé de sulfone
US9409918B2 (en) 2009-10-29 2016-08-09 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
DK2625177T3 (en) 2010-10-08 2015-10-12 Cadila Healthcare Ltd New GPR 119 agonists
MX2013004176A (es) 2010-10-14 2013-10-25 Daiichi Sankyo Co Ltd Derivado de acilbenceno.
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012170867A1 (fr) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Nouveaux composes utilises comme modulateurs de gpr-119
AU2012291150A1 (en) 2011-07-29 2014-02-20 Daiichi Sankyo Company, Limited N-hetero-ring-substituted amide derivative
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013062837A1 (fr) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Dérivés de la pipéridine utilisés comme agonistes du récepteur gpr119
EP3009433B1 (fr) * 2012-01-18 2017-06-21 Daiichi Sankyo Company, Limited Dérivés de 2-phényl-1,3-oxazole et 5-phényl-1,2,4-oxadiazole pour le traitement du diabète
CA2878625A1 (fr) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour reduire un risque cardiometabolique
EP2880027B1 (fr) * 2012-08-02 2016-09-28 Boehringer Ingelheim International GmbH N-cyclopropyl-n-pipéridinyl-amides, compositions pharmaceutiques les contenant et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032965A1 (fr) * 1994-06-01 1995-12-07 Yamanouchi Pharmaceutical Co. Ltd. Derive de l'oxadiazole et composition medicinale a base de ce dernier
US6699853B2 (en) * 1997-06-16 2004-03-02 Hoechst Schering Agrevo Gmbh 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides
AR032292A1 (es) * 1999-12-16 2003-11-05 Schering Corp Imidazoles sustituidos, composiciones farmaceuticas y el uso de dichos imidazoles para la manufactura de un medicamento para los tratamientos de desordenes en la alimentacion
EP3345895B1 (fr) * 2003-04-11 2019-12-04 PTC Therapeutics, Inc. Composé d'acide benzoïque 1,2,4-oxadiazole et son utilisation pour la suppression non-sens et le traitement de maladies
CN1898235A (zh) * 2003-12-24 2007-01-17 普罗西迪恩有限公司 作为gpcr受体激动剂的杂环衍生物
JP5114395B2 (ja) * 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
US20090203676A1 (en) * 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists

Also Published As

Publication number Publication date
JP2009532453A (ja) 2009-09-10
NZ571869A (en) 2011-11-25
WO2007116229A1 (fr) 2007-10-18
EP2013201A1 (fr) 2009-01-14
MX2008012814A (es) 2008-10-17
AU2007235673A1 (en) 2007-10-18
BRPI0710839A2 (pt) 2011-08-23
ZA200809289B (en) 2012-06-27
WO2007116229A8 (fr) 2007-12-27
US20090221639A1 (en) 2009-09-03
KR20080109075A (ko) 2008-12-16
CA2646676A1 (fr) 2007-10-18
EP2013201B1 (fr) 2012-07-25

Similar Documents

Publication Publication Date Title
NO20084307L (no) Heterocykliske GPCR agonister
NO20084364L (no) Azetidin derivater som G-protein koblet reseptor (GPR119) agonister
ATE523507T1 (de) Piperidin-gpcr-agonisten
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
NO20080010L (no) GPCR-agonister
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
NO20080052L (no) G-Protein kopplede reseptoragonister
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
WO2007003961A3 (fr) Agonistes de gpcr
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
JO2681B1 (en) Indole derivatives
NO20085257L (no) Purinonderivater som HM74a-agonister
EA200970090A1 (ru) Модуляторы метаболизма и лечение связанных с ним расстройств
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
UA97257C2 (en) Indole derivatives
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20084403L (no) Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20065868L (no) Substituerte aryl- og heteroarylderivater som metabolisme- og profylkasemodulatorer og behandling av forstyrrelser forbundet med dette
MX2012000704A (es) Agonistas de gpr119.
NO20085099L (no) Puritonderivativer som HM74A agonister
WO2010052144A3 (fr) Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application